BidaskClub upgraded shares of United Therapeutics (NASDAQ:UTHR) from a hold rating to a buy rating in a research report released on Tuesday, September 18th.
A number of other equities research analysts have also recently weighed in on the stock. TheStreet cut shares of United Therapeutics from a b rating to a c+ rating in a research report on Thursday, September 6th. Wedbush set a $253.00 price objective on shares of United Therapeutics and gave the company a buy rating in a report on Tuesday, September 4th. HC Wainwright set a $95.00 price objective on shares of United Therapeutics and gave the company a hold rating in a report on Monday, August 13th. Credit Suisse Group downgraded shares of United Therapeutics from a neutral rating to an underperform rating in a research note on Wednesday, August 8th. Finally, Cowen reiterated a hold rating and issued a $110.00 price target on shares of United Therapeutics in a research note on Thursday, August 2nd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the stock. United Therapeutics currently has an average rating of Hold and an average price target of $138.86.
United Therapeutics stock traded up $1.73 during midday trading on Tuesday, hitting $123.11. 280,107 shares of the stock were exchanged, compared to its average volume of 378,544. United Therapeutics has a fifty-two week low of $100.57 and a fifty-two week high of $152.55. The stock has a market cap of $5.57 billion, a P/E ratio of 11.30, a PEG ratio of 28.86 and a beta of 1.20. The company has a current ratio of 4.64, a quick ratio of 4.35 and a debt-to-equity ratio of 0.10.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share for the quarter, beating analysts’ consensus estimates of $2.57 by $1.41. United Therapeutics had a net margin of 40.87% and a return on equity of 34.42%. The business had revenue of $444.50 million during the quarter, compared to analysts’ expectations of $368.63 million. During the same period last year, the business earned $4.37 earnings per share. The business’s revenue for the quarter was up .0% on a year-over-year basis. As a group, analysts forecast that United Therapeutics will post 14.77 EPS for the current year.
In related news, Director Richard Giltner sold 3,240 shares of the company’s stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher Causey sold 810 shares of the company’s stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the completion of the sale, the director now owns 3,925 shares of the company’s stock, valued at approximately $463,150. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,860 shares of company stock valued at $611,161. 8.20% of the stock is owned by insiders.
Several large investors have recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of United Therapeutics by 2.3% during the 2nd quarter. BlackRock Inc. now owns 5,028,058 shares of the biotechnology company’s stock worth $568,925,000 after purchasing an additional 115,073 shares during the period. Palo Alto Investors LP grew its stake in shares of United Therapeutics by 1.0% during the 1st quarter. Palo Alto Investors LP now owns 1,622,631 shares of the biotechnology company’s stock worth $182,319,000 after purchasing an additional 16,381 shares during the period. Renaissance Technologies LLC grew its stake in shares of United Therapeutics by 1.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,556,200 shares of the biotechnology company’s stock worth $176,084,000 after purchasing an additional 22,322 shares during the period. Acadian Asset Management LLC acquired a new position in shares of United Therapeutics during the 2nd quarter worth $129,555,000. Finally, Dimensional Fund Advisors LP grew its stake in shares of United Therapeutics by 3.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 990,685 shares of the biotechnology company’s stock worth $112,093,000 after purchasing an additional 32,611 shares during the period. 95.83% of the stock is currently owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: Put Option
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.